{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T05:08:51Z","timestamp":1723871331173},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.thromres.2013.09.008","type":"journal-article","created":{"date-parts":[[2013,9,13]],"date-time":"2013-09-13T11:02:04Z","timestamp":1379070124000},"page":"558-564","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers"],"prefix":"10.1016","volume":"132","author":[{"given":"Ryo","family":"Nishio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Shinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromasa","family":"Otake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Hariki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Osue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritoshi","family":"Hiranuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihide","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Kinutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2013.09.008_bb0005","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.09.008_bb0010","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.09.008_bb0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","author":"Sibbing","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2013.09.008_bb0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase-1 is a major determinant of clopidogrel efficacy","volume":"17","author":"Bouman","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.thromres.2013.09.008_bb0025","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/clpt.2011.194","article-title":"Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response","volume":"90","author":"Lewis","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2013.09.008_bb0030","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/eurheartj\/ehr155","article-title":"No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting","volume":"32","author":"Sibbing","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2013.09.008_bb0035","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0009-9236(96)90214-3","article-title":"Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population","volume":"60","author":"Kubota","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2013.09.008_bb0040","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1161\/CIRCULATIONAHA.107.696732","article-title":"Bedside evaluation of thienopyridine antiplatelet therapy","volume":"119","author":"Price","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2013.09.008_bb0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/CIRCGENETICS.108.811638","article-title":"Determination of paraoxonase 1 status without the use of toxic organophosphate substrates","volume":"1","author":"Richter","year":"2008","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.thromres.2013.09.008_bb0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1253\/circj.CJ-09-0690","article-title":"Comparison by optical coherence tomography of paclitaxel-eluting stents with sirolimus-eluting stents implanted in one coronary artery in one procedure. - 6-month follow-up","volume":"74","author":"Miyoshi","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.thromres.2013.09.008_bb0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jcin.2009.03.003","article-title":"Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography","volume":"2","author":"Otake","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.thromres.2013.09.008_bb0060","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.amjcard.2006.01.031","article-title":"Assessment of coronary arterial thrombus by optical coherence tomography","volume":"97","author":"Kume","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.thromres.2013.09.008_bb0065","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1161\/CIRCULATIONAHA.107.187397","article-title":"Universal definition of myocardial infarction","volume":"116","author":"Thygesen","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2013.09.008_bb0070","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","article-title":"Stent thrombosis in randomized clinical trials of drug-eluting stents","volume":"356","author":"Mauri","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.09.008_bb0075","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2013.09.008_bb0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/FPC.0b013e328333dafe","article-title":"Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation","volume":"20","author":"Harmsze","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.thromres.2013.09.008_bb0085","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2710.2009.01069.x","article-title":"Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles","volume":"35","author":"Kim","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.thromres.2013.09.008_bb0090","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/clpt.2010.268","article-title":"Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine","volume":"89","author":"Maeda","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2013.09.008_bb0095","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1253\/circj.CJ-09-0019","article-title":"Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan","volume":"73","author":"Jinnai","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.thromres.2013.09.008_bb0100","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1538-7836.2008.03050.x","article-title":"The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects","volume":"6","author":"Umemura","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.09.008_bb0105","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.thromres.2013.09.008_bb0110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bcp.2010.11.008","article-title":"Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on","volume":"81","author":"Costa","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.thromres.2013.09.008_bb0115","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4244\/EIJV6I3A63","article-title":"Intravascular ultrasound, angioscopic and histopathological characterisation of heterogeneous patterns of restenosis after sirolimus-eluting stent implantation: insights into potential \"thromborestenosis\" phenomenon","volume":"6","author":"Oikawa","year":"2010","journal-title":"EuroIntervention"},{"key":"10.1016\/j.thromres.2013.09.008_bb0120","doi-asserted-by":"crossref","first-page":"604","DOI":"10.5551\/jat.6965","article-title":"Origin of restenosis after drug-eluting stent implantation in hyperglycemia is inflammatory cells and thrombus","volume":"18","author":"Kwon","year":"2011","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.thromres.2013.09.008_bb0125","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jacc.2008.05.032","article-title":"Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents","volume":"52","author":"Gori","year":"2008","journal-title":"J Am Coll Cardiol"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813004088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813004088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T03:57:20Z","timestamp":1539403040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384813004088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0049384813004088"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2013.09.008","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2013.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}